Cardiovascular Systems (CSII) 26.08 $CSII
Cardiovascular Systems Down 17.5% Since SmarTrend Downtrend Call (CSII)
Comtex SmarTrend(R) - Wed Apr 16, 9:38AM CDT
SmarTrend identified a Downtrend for Cardiovascular Systems (NASDAQ:CSII) on March 25th, 2014 at $32.25. In approximately 3 weeks, Cardiovascular Systems has returned 17.52% as of today's recent price of $26.59.
Cardiovascular Systems Has Returned 12.5% Since SmarTrend Recommendation (CSII)
Comtex SmarTrend(R) - Wed Apr 09, 9:15AM CDT
SmarTrend identified a Downtrend for Cardiovascular Systems (NASDAQ:CSII) on March 25th, 2014 at $32.25. In approximately 2 weeks, Cardiovascular Systems has returned 12.54% as of today's recent price of $28.20.
Use Options For A Chance To Buy CSII At A 28% Discount
at The Street - Wed Apr 02, 10:57AM CDT
Looking back to 133 days ago, Cardiovascular Systems, Inc priced a 2,608,696 share secondary stock offering at $30 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over...
Cardiovascular Systems Presenting ORBIT II Study One-Year Coronary Data During 2014 American College of Cardiology Conference
Business Wire - Wed Mar 26, 10:32AM CDT
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), will feature one-year data from the ORBIT II study of the company's Diamondback 360(R) Coronary Orbital Atherectomy System. The study, which is one of the first to investigate treating severely calcified lesions, will be presented at the 2014 American College of Cardiology (ACC) conference in Washington, D.C., Mar. 29-31, 2014. This data, along with physician presentations that include case studies and commercial data, are part of CSI's series of in-booth live talks at ACC.
Research and Markets: Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating
Business Wire - Tue Mar 25, 1:22PM CDT
Research and Markets (http://www.researchandmarkets.com/research/t86twq/global) has announced the addition of the "Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating" report to their offering.
Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating
M2 - Tue Mar 25, 10:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3c75md/global) has announced the addition of the "Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating" report to their offering. The Global Atherectomy and Thrombectomy Devices market to grow at a CAGR of 9.36 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing prevalence of abdominal aortic aneurysm and peripheral artery disease. The Global Atherectomy and Thrombectomy Devices market has also been witnessing the increase in demand for minimally invasive procedures. However, the lack of awareness about peripheral vascular disease among patients could pose a challenge to the growth of this market. There is an increasing demand for minimally invasive surgery among the rapidly increasing aging population in the world, and this is expected to propel the growth of the Global Atherectomy and Thrombectomy Devices market. Minimally invasive endovascular procedures are performed through minute incisions in the body. Such procedures can be used to treat plaque blockages in the arteries of the heart and other vessel walls of peripheral organs such as kidneys and brain. The principal advantages of these procedures, over conventional surgical methods, are the short recovery time, less physical trauma, minimal scarring, low risk of infection, minimal bleeding, low cost, and shorter hospital stays. Therefore, the increasing demand for minimally invasive surgery is expected to increase the demand for atherectomy and thrombectomy devices during the forecast period. Further, the report states that one of the major challenges faced by vendors in the market is the lack of awareness about PVDs among patients. This is primarily due to the asymptomatic nature of vascular diseases, wherein patients do not realize and are unaware of the immediate symptoms. The key vendors dominating this market space are: - Bayer AG - Boston Scientific Corp. - Covidien plc - Cardiovascular Systems Inc. - Spectranetics Corp. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Global Atherectomy and Thrombectomy Market 07. Market Segmentation by Product Category 08. Geographical Segmentation 09. Global Atherectomy Market 10. Market Segmentation by Product Type 11. Geographical Segmentation 12. Global Thrombectomy Devices Market 13. Market Segmentation by Procedure 14. Geographical Segmentation 15. Buying Criteria 16. Market Growth Drivers 17. Drivers and their Impact 18. Market Challenges 19. Impact of Drivers and Challenges 20. Market Trends 21. Trends and their Impact 22. Vendor Landscape For more information visit http://www.researchandmarkets.com/research/3c75md/global
Supply Agreements, Patents, Appointments, and FDA Clearances - Analyst Notes on OPKO, Synageva, Hill-Rom, Anacor, and Cardiovascular Systems
PR Newswire - Thu Mar 20, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding OPKO Health, Inc. (NYSE: OPK), Synageva BioPharma Corp. (NASDAQ: GEVA), Hill-Rom Holdings, Inc. (NYSE: HRC), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), and Cardiovascular Systems Inc. (NASDAQ: CSII). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cardiovascular Systems Announces First Peripheral Arterial Disease Case Treated with New, Low-Profile, 60cm Diamondback Peripheral System
Business Wire - Wed Mar 12, 10:00AM CDT
Cardiovascular Systems, Inc. (NASDAQ: CSII) (CSI), today announced the first use of its Diamondback 360(R) 60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD). Jihad A. Mustapha, M.D., FACC, FSCAI, Director of Heart and Vascular at Metro Health Hospital in Wyoming, Mich., performed the procedure through Tibiopedal access using the new, low-profile device.
Cardiovascular Systems Receives FDA Clearance for Low Profile, 60cm Diamondback Devices Designed to Expand the Treatment of Peripheral Artery Disease (PAD)
Business Wire - Mon Mar 10, 7:01AM CDT
Cardiovascular Systems, Inc. (NASDAQ: CSII) (CSI), announced today it has received FDA clearance of its new Diamondback 360(R) 60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD).
Cardiovascular Systems Releases One-Year Orbit II Coronary Data at 2014 Cardiovascular Research Technologies Conference
Business Wire - Tue Feb 25, 6:01AM CST
--Cost savings in excess of $4,000 per patient treated versus current standard of care
Cardiovascular Systems to Present ORBIT II Coronary Data at 2014 Cardiovascular Research Technologies Conference
Business Wire - Thu Feb 20, 10:15AM CST
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), will release one-year data from the ORBIT II study of the company's Diamondback 360(R) Coronary Orbital Atherectomy System in treating severely calcified lesions. The data will be presented as an iMPACT Trial at the 2014 Cardiovascular Research Technologies (CRT) conference in Washington, D.C., Feb. 22-25, 2014. CRT's iMPACT Trials are innovative reports that provide the latest breakthroughs in clinical science. The studies selected for the iMPACT Trials session at CRT are expected to highlight new improvements for quality of patient care, and significantly impact the field of interventional cardiology.
T-Mobile Austria Selects NetScout to Assure National LTE Network
Business Wire - Wed Feb 19, 7:30AM CST
NetScout(R) Systems, Inc. today announced that T-Mobile Austria has selected NetScout to assure service delivery and provide operational intelligence for their national Long Term Evolution (LTE) network, expanding NetScout's existing deployment in T-Mobile's third-generation (3G) HSPA+ network. The nGenius(R) solution provides T-Mobile with a single service assurance platform to support data and multimedia services to assure a seamless subscriber experience on and between their 2G, 3G and LTE networks.
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 30, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Cardiovascular Systems, Inc. Shares Are Feeling Pumped
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 30, 1:30PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cardiovascular Systems , a medical device...
Upgrade Alert for Cardiovascular Systems (CSII)
Comtex SmarTrend(R) - Thu Jan 30, 8:00AM CST
Cardiovascular Systems (NASDAQ:CSII) was upgraded from Hold to Buy at Benchmark Co. today. The stock closed yesterday at $29.41 on volume of 377,000 shares, above average daily volume of 294,000. In the past 52 weeks, Cardiovascular Systems share prices have been bracketed by a low of $13.28 and a high of $34.72 and closed yesterday at $29.41, 121% above that low price. The 200-day and 50-day moving averages have moved 0.67% higher and 0.12% lower over the past week, respectively.
Cardiovascular Systems Reports Fiscal 2014 Second-Quarter Financial Results
Business Wire - Wed Jan 29, 3:00PM CST
--Revenues rose 28 percent for both the second quarter and first half of fiscal 2014
Covidien Beats on Q1 Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 1:41PM CST
Covidien posted first-quarter fiscal 2014 adjusted earnings per share from continuing operations of $1.00, up 3.09% year over year.
FDA OKs Covidien's Novel Jaw Device - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 6:00PM CST
Covidien's LigaSure Maryland jaw gets the FDA approval.
Cardiovascular Systems Down 17.5% Since SmarTrend Downtrend Call (CSII)
Comtex SmarTrend(R) - Wed Apr 16, 9:38AM CDT
SmarTrend identified a Downtrend for Cardiovascular Systems (NASDAQ:CSII) on March 25th, 2014 at $32.25. In approximately 3 weeks, Cardiovascular Systems has returned 17.52% as of today's recent price of $26.59.
Cardiovascular Systems Has Returned 12.5% Since SmarTrend Recommendation (CSII)
Comtex SmarTrend(R) - Wed Apr 09, 9:15AM CDT
SmarTrend identified a Downtrend for Cardiovascular Systems (NASDAQ:CSII) on March 25th, 2014 at $32.25. In approximately 2 weeks, Cardiovascular Systems has returned 12.54% as of today's recent price of $28.20.
Use Options For A Chance To Buy CSII At A 28% Discount
at The Street - Wed Apr 02, 10:57AM CDT
Looking back to 133 days ago, Cardiovascular Systems, Inc priced a 2,608,696 share secondary stock offering at $30 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over...
Cardiovascular Systems Presenting ORBIT II Study One-Year Coronary Data During 2014 American College of Cardiology Conference
Business Wire - Wed Mar 26, 10:32AM CDT
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), will feature one-year data from the ORBIT II study of the company's Diamondback 360(R) Coronary Orbital Atherectomy System. The study, which is one of the first to investigate treating severely calcified lesions, will be presented at the 2014 American College of Cardiology (ACC) conference in Washington, D.C., Mar. 29-31, 2014. This data, along with physician presentations that include case studies and commercial data, are part of CSI's series of in-booth live talks at ACC.
Research and Markets: Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating
Business Wire - Tue Mar 25, 1:22PM CDT
Research and Markets (http://www.researchandmarkets.com/research/t86twq/global) has announced the addition of the "Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating" report to their offering.
Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating
M2 - Tue Mar 25, 10:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3c75md/global) has announced the addition of the "Global Atherectomy and Thrombectomy Devices Market 2014-2018 with Bayer, Boston Scientific, Covidien, Cardiovascular Systems & Spectranetics Dominating" report to their offering. The Global Atherectomy and Thrombectomy Devices market to grow at a CAGR of 9.36 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing prevalence of abdominal aortic aneurysm and peripheral artery disease. The Global Atherectomy and Thrombectomy Devices market has also been witnessing the increase in demand for minimally invasive procedures. However, the lack of awareness about peripheral vascular disease among patients could pose a challenge to the growth of this market. There is an increasing demand for minimally invasive surgery among the rapidly increasing aging population in the world, and this is expected to propel the growth of the Global Atherectomy and Thrombectomy Devices market. Minimally invasive endovascular procedures are performed through minute incisions in the body. Such procedures can be used to treat plaque blockages in the arteries of the heart and other vessel walls of peripheral organs such as kidneys and brain. The principal advantages of these procedures, over conventional surgical methods, are the short recovery time, less physical trauma, minimal scarring, low risk of infection, minimal bleeding, low cost, and shorter hospital stays. Therefore, the increasing demand for minimally invasive surgery is expected to increase the demand for atherectomy and thrombectomy devices during the forecast period. Further, the report states that one of the major challenges faced by vendors in the market is the lack of awareness about PVDs among patients. This is primarily due to the asymptomatic nature of vascular diseases, wherein patients do not realize and are unaware of the immediate symptoms. The key vendors dominating this market space are: - Bayer AG - Boston Scientific Corp. - Covidien plc - Cardiovascular Systems Inc. - Spectranetics Corp. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Global Atherectomy and Thrombectomy Market 07. Market Segmentation by Product Category 08. Geographical Segmentation 09. Global Atherectomy Market 10. Market Segmentation by Product Type 11. Geographical Segmentation 12. Global Thrombectomy Devices Market 13. Market Segmentation by Procedure 14. Geographical Segmentation 15. Buying Criteria 16. Market Growth Drivers 17. Drivers and their Impact 18. Market Challenges 19. Impact of Drivers and Challenges 20. Market Trends 21. Trends and their Impact 22. Vendor Landscape For more information visit http://www.researchandmarkets.com/research/3c75md/global
Supply Agreements, Patents, Appointments, and FDA Clearances - Analyst Notes on OPKO, Synageva, Hill-Rom, Anacor, and Cardiovascular Systems
PR Newswire - Thu Mar 20, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding OPKO Health, Inc. (NYSE: OPK), Synageva BioPharma Corp. (NASDAQ: GEVA), Hill-Rom Holdings, Inc. (NYSE: HRC), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), and Cardiovascular Systems Inc. (NASDAQ: CSII). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cardiovascular Systems Announces First Peripheral Arterial Disease Case Treated with New, Low-Profile, 60cm Diamondback Peripheral System
Business Wire - Wed Mar 12, 10:00AM CDT
Cardiovascular Systems, Inc. (NASDAQ: CSII) (CSI), today announced the first use of its Diamondback 360(R) 60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD). Jihad A. Mustapha, M.D., FACC, FSCAI, Director of Heart and Vascular at Metro Health Hospital in Wyoming, Mich., performed the procedure through Tibiopedal access using the new, low-profile device.
Cardiovascular Systems Receives FDA Clearance for Low Profile, 60cm Diamondback Devices Designed to Expand the Treatment of Peripheral Artery Disease (PAD)
Business Wire - Mon Mar 10, 7:01AM CDT
Cardiovascular Systems, Inc. (NASDAQ: CSII) (CSI), announced today it has received FDA clearance of its new Diamondback 360(R) 60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD).
Cardiovascular Systems Releases One-Year Orbit II Coronary Data at 2014 Cardiovascular Research Technologies Conference
Business Wire - Tue Feb 25, 6:01AM CST
--Cost savings in excess of $4,000 per patient treated versus current standard of care
Cardiovascular Systems to Present ORBIT II Coronary Data at 2014 Cardiovascular Research Technologies Conference
Business Wire - Thu Feb 20, 10:15AM CST
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), will release one-year data from the ORBIT II study of the company's Diamondback 360(R) Coronary Orbital Atherectomy System in treating severely calcified lesions. The data will be presented as an iMPACT Trial at the 2014 Cardiovascular Research Technologies (CRT) conference in Washington, D.C., Feb. 22-25, 2014. CRT's iMPACT Trials are innovative reports that provide the latest breakthroughs in clinical science. The studies selected for the iMPACT Trials session at CRT are expected to highlight new improvements for quality of patient care, and significantly impact the field of interventional cardiology.
T-Mobile Austria Selects NetScout to Assure National LTE Network
Business Wire - Wed Feb 19, 7:30AM CST
NetScout(R) Systems, Inc. today announced that T-Mobile Austria has selected NetScout to assure service delivery and provide operational intelligence for their national Long Term Evolution (LTE) network, expanding NetScout's existing deployment in T-Mobile's third-generation (3G) HSPA+ network. The nGenius(R) solution provides T-Mobile with a single service assurance platform to support data and multimedia services to assure a seamless subscriber experience on and between their 2G, 3G and LTE networks.
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 30, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Cardiovascular Systems, Inc. Shares Are Feeling Pumped
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 30, 1:30PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cardiovascular Systems , a medical device...
Upgrade Alert for Cardiovascular Systems (CSII)
Comtex SmarTrend(R) - Thu Jan 30, 8:00AM CST
Cardiovascular Systems (NASDAQ:CSII) was upgraded from Hold to Buy at Benchmark Co. today. The stock closed yesterday at $29.41 on volume of 377,000 shares, above average daily volume of 294,000. In the past 52 weeks, Cardiovascular Systems share prices have been bracketed by a low of $13.28 and a high of $34.72 and closed yesterday at $29.41, 121% above that low price. The 200-day and 50-day moving averages have moved 0.67% higher and 0.12% lower over the past week, respectively.
Cardiovascular Systems Reports Fiscal 2014 Second-Quarter Financial Results
Business Wire - Wed Jan 29, 3:00PM CST
--Revenues rose 28 percent for both the second quarter and first half of fiscal 2014
Covidien Beats on Q1 Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 1:41PM CST
Covidien posted first-quarter fiscal 2014 adjusted earnings per share from continuing operations of $1.00, up 3.09% year over year.
FDA OKs Covidien's Novel Jaw Device - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 6:00PM CST
Covidien's LigaSure Maryland jaw gets the FDA approval.
